Hosted on MSN2mon
FDA Adds Guillain-Barre Syndrome Warning to Two RSV Vaccines
The FDA issued a safety communication that warns about possible Guillain-Barré syndrome (GBS) with respiratory syncytial virus (RSV) vaccines manufactured by Pfizer (Abrysvo) and GSK (Arexvy).
pharmaphorum5d
GSK targets younger age group with RSV jab Arexvy
GSK has reported new clinical data pointing to a benefit with its respiratory syncytial virus (RSV) vaccine Arexvy when used to treat a younger age group than the over-60s for whom it is approved.
SBS1y
Australia approved it's first RSV Vaccine. Will you be eligible for this now?
The Therapeutic Goods Administration (TGA) has approved AREXVY to be used as a RSV vaccine for Australians aged 60 and over.
pharmaphorum5d
GSK to lean on Zhifei for Shingrix and maybe Arexvy in China
The arrangement will run for three years in the first instance and, according to GSK, also “supports potential future co-development and commercialisation of Arexvy […] for adults 60 years and ...